Parameter | Value(s) for final model parameters | ||
---|---|---|---|

Final run | Bootstrap (n = 500 runs) | ||

Median estimate | 90% CI | ||

CL/F (liters/h) | 2.96 | 2.96 | 2.87–3.05 |

V_{2}/F (liters) | 915 | 913 | 879–956 |

Q/F (liters/h) | 5.09 | 5.10 | 4.76–5.43 |

V_{3}/F (liters) | 664 | 665 | 634–692 |

Absorption lag time (h) | 0.908 | 0.930 | 0.904–0.950 |

K (h_{a}^{−1}) | 0.252 | 0.254 | 0.226–0.296 |

Capsule effect on K_{a} | 0.924 | 0.914 | 0.805–1.03 |

Relative bioavailability (capsule) | 0.863 | 0.866 | 0.833–0.900 |

V_{2}/F ratio (healthy volunteers/patients) | 1.35 | 1.35 | 1.30–1.41 |

V_{3}/F ratio (healthy volunteers/patients) | 0.347 | 0.340 | 0.295–0.396 |

IIV CL/F | 32.1 | 32.0 | 30.0–34.1 |

IIV V_{2}/F | 34.4 | 34.3 | 31.8–37.1 |

IIV CL-V_{2} block | 33.3 | 29.9 | 27.7–32.5 |

IIV K_{a} | 40.4 | 39.6 | 31.7–48.0 |

IIV ALAG1 | 44.3 | 43.4 | 38.8–56.1 |

IIV error | 33.0 | 33.2 | 27.2–38.5 |

Random residual variability (% CV) | 15.0 | 14.9 | 14.3–15.8 |

↵a

*K*, absorption rate constant; CL/_{a}*F*, oral clearance from the central compartment;*V*_{2}/*F*, volume of distribution for the central compartment;*V*_{3}/*F*, volume of distribution for the peripheral compartment;*Q*/*F*, intercompartmental clearance; IIV, interindividual variability, expressed as the percent coefficient of variation; CI, confidence interval. The tablet formulation was considered the reference, i.e.,*F*1_{tablet}= 1.